Combination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamsters.
2-(2"-Dichloroacetamidobenzyl)-3-(3'-indolylquinoline), designated indolylquinoline derivative A, reduced the splenic and the liver parasite burdens by >93.0% in Leishmania donovani-infected hamsters, whereas sodium antimony gluconate (SAG) reduced the burdens approximately 80.0%. Complete clearance of parasitemia from the livers and spleens was noticed when infected animals received indolylquinoline derivative A plus SAG, suggesting that indolylquinoline derivative A has potential as a new agent for sole or conjunctive therapy for leishmaniasis.
Pal
Chiranjib
C
Immunology Division, Indian Institute of Chemical Biology, Jadavpur, Kolkata-700 032, India.
Raha
Mousumi
M
Basu
Anirban
A
Roy
Keshab Chandra
KC
Gupta
Anasuya
A
Ghosh
Monidipa
M
Sahu
Niranjan Prasad
NP
Banerjee
Sukdeb
S
Mandal
Nirup Bikash
NB
Bandyopadhyay
Santu
S
D000818:Animals; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D006224:Cricetinae; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D007211:Indoles / Q000627:therapeutic use*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D011804:Quinolines / Q000627:therapeutic use*; D016896:Treatment Outcome
C443758:2-(2''-dichloroacetamidobenzyl)-3-(3'-indolylquinoline); D000981:Antiprotozoal Agents; D007211:Indoles; D011804:Quinolines; D000967:Antimony Sodium Gluconate